Travere Therapeutics (TVTX) Competitors

Travere Therapeutics (NASDAQ:TVTX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.

Which has better earnings and valuation, TVTX or HROW?

Harrow has lower revenue, but higher earnings than Travere Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$145.24M	9.52	-$111.40M	-$4.55	-3.89
Harrow	$130.19M	10.63	-$24.41M	-$0.94	-41.50

Do institutionals & insiders have more ownership in TVTX or HROW?

72.8% of Harrow shares are owned by institutional investors. 3.8% of Travere Therapeutics shares are owned by insiders. Comparatively, 13.7% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer TVTX or HROW?

Harrow received 11 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 58.28% of users gave Harrow an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote.

Company	Underperform	Outperform
Travere Therapeutics	Outperform Votes 77 57.04%	Underperform Votes 58 42.96%
Harrow	Outperform Votes 88 58.28%	Underperform Votes 63 41.72%

Is TVTX or HROW more profitable?

Harrow has a net margin of -19.75% compared to Travere Therapeutics' net margin of -172.75%. Harrow's return on equity of -44.61% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-172.75%	-537.74%	-55.65%
Harrow	-19.75%	-44.61%	-9.21%

Do analysts prefer TVTX or HROW?

Travere Therapeutics currently has a consensus target price of $22.62, indicating a potential upside of 27.63%. Harrow has a consensus target price of $56.67, indicating a potential upside of 45.26%. Given Harrow's stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Harrow	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, TVTX or HROW?

Travere Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Does the media prefer TVTX or HROW?

In the previous week, Harrow had 16 more articles in the media than Travere Therapeutics. MarketBeat recorded 23 mentions for Harrow and 7 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 0.74 beat Harrow's score of 0.67 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harrow	8 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harrow beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks.